At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 156 enrolled
Drug / intervention
Gefitinibdrug
Likely dose
Gefitinib 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients
In Brief
A Phase 4 clinical trial evaluating Gefitinib for Non Small Cell Lung Carcinoma. Completed, enrolled 156 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid Tumors Group) and check up ORR difference by EGFR mutation, gender, smoking history, and type of tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Carcinoma
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedFeb 2008
Primary CompletionJan 2009
TodayJul 2026
First PostedFeb 6, 2008
Enrollment StartJan 1, 2007
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.4 years ago
Interventions
Gefitinibdrug
Gefitinib tablet 250mg once daily orally